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Abstract
Rationale: Bronchial involvement alone is a rare initial manifestation of granulomatosis with polyangiitis (GPA). Herein, we report a
case of refractory GPA with obstructive pneumonia caused by bronchial involvement.
Patient concerns: A 65-year-old man complained of a 2-week cough and fever.
Diagnoses: Considering the presence of opacities and multiple consolidations in both lungs due to obstruction or stenosis on the
bronchus, which did not respond to antibiotics, andproteinase-3-antineutrophil cytoplasmic autoantibody positivity, hewasdiagnosed
with GPA. Positron emission tomography- computed tomography scan revealed no abnormal findings in the upper respiratory tract.
Interventions: He was treated with prednisolone (PSL, 50mg/d) and intravenous cyclophosphamide.
Outcomes:His general and respiratory symptoms improved. However, 8 weeks after PSL treatment at 20mg/d, he developed a
relapse of vasculitis along with sinusitis and hypertrophic pachymeningitis. Hence, PSL treatment was resumed to 50mg/d, and
weekly administration of rituximab was initiated. Consequently, the symptoms gradually mitigated.
Lessons:GPAwith bronchial involvement is often intractable and requires careful follow-up, which should include upper respiratory
tract and hypertrophic pachymeningitis assessment.
Abbreviations: ANCA = antineutrophil cytoplasmic autoantibody, BS = bronchial stenosis, CT = computed tomography, CYC =
cyclophosphamide, ENT= ear, nose, and throat, GPA= granulomatosis with polyangiitis, HP= hypertrophic pachymeningitis, MRI=
magnetic resonance imaging, PR3 = proteinase-3, PSL = prednisolone, RTX = rituximab, TBS = tracheobronchial stenosis.
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1. Introduction
Granulomatosis with polyangiitis (GPA) is one of the
antineutrophil cytoplasmic autoantibody (ANCA)-associated
vasculitides; it is a systemic, granulomatous, and necrotizing
vasculitis that involves small- and medium-sized blood
vessels and commonly affects the upper and lower respiratory
tract.[1]
Severe bronchial stenosis (BS) is a rare initial respiratory
involvement in GPA. Subglottic stenosis and tracheobronchial
stenosis (TBS) distal to the glottis are reportedly observed in 12%
to 23% of the GPA cases,[2–5] whereas severe BS has been
reported in only 4% of GPA cases with pulmonary manifes-
tations.[6] BS without the ear, nose, and throat (ENT) involve-
ment has never been reported in GPA cases with BS. The
tracheobronchial involvement is often intractable and requires
multidisciplinary approaches, such as surgical intervention and
local glucocorticoid injection.[7–9] Although glucocorticoid
combined with cyclophosphamide (CYC) or rituximab (RTX)
is a recommended standard treatment for GPA, the appropriate
treatment strategy for GPA with BS remains uncertain.
Herein, we report a patient with GPA who initially presented
with only BS and experienced relapse with sinusitis and
hypertrophic pachymeningitis (HP). The patient was then
successfully treated with RTX.
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A 65-year-old man was admitted to a community hospital with a
2-week history of cough and >38°C body temperature.
Computed tomography (CT) of the lungs revealed that both
lungs exhibited opacities and multiple consolidations (Fig. 1A).
Initially, he was treated with antibiotics, but no signs of
improvement were noted. Bronchoscopy was then conducted,
which revealed that the bronchus of the right middle lobe was
obstructed and that of the left upper lobe was red and fragile
without active hemorrhage. Furthermore, proteinase-3 (PR3)-
ANCA was positive; hence, he was transferred to our hospital at
4 weeks after the onset of symptoms.
Upon admission, he had persistent fever, weight loss, and
cough but without symptoms involving ENT. Physical examina-
tion revealed the following: height, 168cm; weight, 48kg; body
temperature, 37.6°C; and blood pressure, 114/64 mm Hg. No
abnormal findings were detected in the head, neck, chest,
musculoskeletal, and nervous systems. The laboratory findings
were as follows: white blood cell count, 10460/mL (neutrophils:
94.4%); C-reactive protein level, 9.7mg/dL; PR3-ANCA, 16 IU/
mL (cutoff 2.00IU/mL); andMPO-ANCA, negative. Urinalysis
was normal, and the serum creatinine level was 0.52mg/dL.
According to the positron emission tomography-CT scan, 18F-
fluorodeoxyglucose accumulated within both lungs, consistent
with the opacities revealed in CT, but no abnormalities were
found in ENT. CT-guided lung biopsy revealed necrotizing
granulomatous inflammation with remarkable infiltrations of
neutrophils and multinucleated giant cells. Subsequently, the
patient was diagnosed with GPA according to the presence of
chronic lower respiratory symptoms with multiple infiltrates of
the lung and the PR3-ANCA positivity.
After the patient received 50mg/d of prednisolone (PSL) and
intravenous CYC, his general and respiratory symptoms
improved. Four weeks after treatment initiation, chest CT
showed that the consolidations in the right upper lobe of the lung
improved (Fig. 1B). In addition, enhanced magnetic resonance
imaging (MRI) of the head revealed no findings indicative of
sinusitis or HP 4 weeks after treatment initiation (Fig. 2A).
However, 8 weeks after treatment with 20mg/d (0.4mg/kg/d)
of PSL, the patient developed fever, epistaxis, and headache,
with elevations of C-reactive protein levels to 9.2mg/dL and
PR3-ANCA levels to 24IU/mL (Fig. 3). Chest CT detected that the
left upper lobe of the lung consolidated and the bronchial wall
thickened (Fig. 1C). Moreover, contrast-enhanced MRI revealed
the presence of fluid in the left maxillary sinus and the abnormal
dura thickening in themiddle cranial fossa (Fig. 2B). Cerebrospinal
fluid findings included the following; appearance: clear, opening
pressure: 15cm H2O, WBC count: 3cells/mL (mononuclear cells),
glucose level: 100mg/dL, protein level: 105mg/dL, IgG index:
0.58, mycobacterium; negative. There were no evidence of IgG4-
related disease and sarcoidosis. Hence, the patient was diagnosed
to develop a relapse of vasculitis with newly appeared sinusitis and
HP. We then increased the dose of PSL to 50mg/d and initiated
weekly RTX (375mg/m2/wk for 4 weeks) concomitantly. After
receiving re-induction remission treatment, the patient’s fever,
epistaxis, and headache alleviated. Five weeks after this treatment,
theopacitiesnotedon the rightmiddle lobeand left inferior lingular
segment also improved (Fig. 1D). Ten months after the re-
induction treatment, PSL was reduced to 2.5mg/d without any
additional treatment.
3. Discussion
Toour knowledge, this is thefirst case ofGPApresentingwith only
BS that resulted in obstructive pneumonia. The strength of the
present case is that the absence of the upper airway disease at
the presentation was confirmed by the imaging studies. BS alone is
a rare manifestation as the first symptom of GPA. Generally, the
upper respiratory tract is affected before the lower respiratory
tract,[10] and only 9%of patients reportedly did not have anyother
organ involvements other than the lungs.[6]AmongGPAcaseswith
lung involvement, 4% reportedly had severe stenosis leading to
atelectasis.[6] As the limitation in the assessment of this case, MRI
of the head was not conducted before the commencement of
Figure 1. Computed tomography of the chest. (A) At the diagnosis. (B) One
month later from the initiation of remission induction therapy. (C) At the time of
relapse. (D) At 5 weeks after the initiation of re-remission induction therapy. The
white arrowheads indicate the exacerbation of bronchial wall thickness.
Figure 2. Magnetic resonance imaging of the head. (A) One month after the
initiation of remission induction therapy. (B) At the time of relapse. The white
arrow indicates the fluid in the left maxillary sinus, and the white arrowheads
denote gadolinium enhancement of the hypertrophic dura mater.
Hayashi et al. Medicine (2021) 100:3 Medicine
2
treatment. Therefore, HP might be present at the presentation
despite no headache. It has been reported that HP accompanies in
approximately 20% to 30% of GPA patients, and the pathogenic
mechanism is thought to be the spreading of granulomatous tissue
from the nasal, paranasal cavities, or orbit and contiguously
invasion to the adjacent structures including meninges.[11] A
nationwide survey conducted in Japan showed that 34% of
patients with HP were diagnosed with ANCA-associated vasculit-
ides, and 9%of patients with IgG4-related disease.[12] This patient
lacked salivary and lacrimal gland enlargement, orbital disease,
autoimmune pancreatitis, retroperitoneal fibrosis, and tubuloin-
terstitial nephritis; therefore, we have excluded this differential
diagnosis.
Previous reports showed tracheobronchial involvement in
GPA is refractory and sometimes relapses with ENT involve-
ment. It is reported that 62% of the patients with GPA
exhibiting TBS and/or subglottic stenosis experienced relap-
ses.[5,9] Among the patients who experienced relapses with BS,
11% relapsed with ENT symptoms.[9] In another study,
rhinosinusal involvement associated with TBS.[5] The present
case relapsed with not only sinusitis but also HP despite the
absence of ENT involvement at disease onset. Considering that
HP is also refractory,[13] ENT symptoms and HP need to be
monitored carefully during the relapse of the lower respiratory
symptoms.
The present case responded to RTX well in contrast to high-
dose PSL and intravenous CYC. Girard et al described that
RTX was more effective than CYC for treating GPA with BS.[9]
RTX is also reportedly effective for HP,[14,15] and in our case,
the PSL dosage could be reduced without relapses. It is possible
that RTX is a preferred treatment option for GPA patients
with BS.
In conclusion, healthcare providers need to consider not only
lung cancer but also GPA despite the absence of upper airway
symptoms. It also should be recognized that BS inGPA sometimes
exacerbates with ENT involvement and HP during the clinical
course. RTX might be a possible treatment option for GPA with
BS and HP.
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